Role of splenectomy in the treatment of myelofibrosis

Melikyan A.L.; Kolosova L.Iu.; Sokolova M.A.; Kovrigina A.M.; Silaev M.A.; Giliazitdinova E.A.; Gemdzhyan E.G.; Karagiulian S.R.

doi:https://doi.org/

Melikyan A.L.

GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva

ORCID: 0000-0002-2119-3775

Kolosova L.Iu.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Sokolova M.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

Silaev M.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Giliazitdinova E.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Gemdzhyan E.G.

National Research Center for Hematology, Moscow, Russia

Karagiulian S.R.

Gematologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Role of splenectomy in the treatment of myelofibrosis

Authors:

Melikyan A.L., Kolosova L.Iu., Sokolova M.A., Kovrigina A.M., Silaev M.A., Giliazitdinova E.A., Gemdzhyan E.G., Karagiulian S.R.

More about the authors

Journal: Therapeutic Archive. 2013;85(8): 69‑76

Read: 4040 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Melikyan AL, Kolosova LIu, Sokolova MA, et al. Role of splenectomy in the treatment of myelofibrosis. Therapeutic Archive. 2013;85(8):69‑76. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Isolated blunt trauma of the spleen: non-standard solution of standard problem (laparoscopic selective clipping of splenic artery branches). Pirogov Russian Journal of Surgery. 2025;(10):7-13

Abstract:

Aim. To evaluate the clinical and hematologic efficiency of splenectomy (SE) in patients with myelofibrosis (MF) resistant to conventional traditional treatment. Subjects and methods. Case histories were retrospectively analyzed in 52 MF patients who had been followed up at the Hematology Research Center, Ministry of Health of the Russian Federation, in 2004 to 2012 and undergone therapeutic SE (47 patients with primary myelofibrosis, 4 with postpolycythemia myelofibrosis, and 1 with postthrombocythemia myelofibrosis). The mean age was 47 years at diagnosis and 53 years before surgery. The patients younger than 50 years of age constituted 60%. Massive and giant splenomegaly was detected in 37 (71%) patients. The spleen weighing 0.9 to 2.9 and 3 to 7 kg was removed in 15 (29%) and 35 (67%) patients, respectively. In 2 cases, the weight of the removed spleen was as much as 10 and 11 kg. Results. By the moment of SE, the disease duration averaged 76 (from 1 to 240) months. Twenty-one (40%) patients developed perioperative complications, including bleeding (15%), thrombosis (11.5%), and infectious complications (13.5%). There were no deaths from surgical interventions in the intra- and early postoperative periods. In more than 80% of the patients after SE, their general condition improved and the symptoms of intoxication disappeared; in the majority of patients, the therapeutic effect lasted about 2 years. In the follow-up period, 33 (63%) patients died; the time to death averaged 27 (1-84) months following SE. The causes of death were blast transformation in 27 (82%) patients and comorbidity in 6 (18%); 19 (37%) patients with an average post-SE follow-up of 37 (4-72) months continued hydroxyurea treatment. The median survival after SE was equal to 3 years; the median overall survival was 11 years. Conclusion. SE is effective palliative care with an acceptable level of occurring complications for individual patients with MF. Contraindications to SE as blast crisis and severe comorbidities should be strictly taken into account.

Keywords:

myelofibrosis

giant spleen

splenectomy

postsplenectomy survival

blast transformation

surgery complications

multivariate statistical analysis

Authors:

Melikyan A.L.

GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva

ORCID: 0000-0002-2119-3775

Kolosova L.Iu.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Sokolova M.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

Silaev M.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Giliazitdinova E.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Gemdzhyan E.G.

National Research Center for Hematology, Moscow, Russia

Karagiulian S.R.

Gematologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia RF, Moskva

Close metadata

References:

Barosi G. Myeiofibrosis with myeloid metaplasis diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954 -2970.
Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520-8530.
Mesa R.A., Verstjvsek S., Cervantes F. et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post PV MF), post essential thrombocythemia myelofibrosis (post ET MF), blast phas PMF (PMF BP): consensus on terminology by the international Working Group tor Myelofibrosis Research and Tratment (IWG-MRT). Leuk Res 2007; 31: 737-740.
Barosi G., Mesa R.A., Thiele J. et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
Tefferi A., Thiele J., Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
Cervantes F., Dupriez B., Pereira A. et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
Kralowics R., Passamonti F., Buder A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
Levine R.L., Wadleigh M., Cool J. et al. Activation mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
Pikman Y., Lee B.H., Mercher T. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PloS Med 2006; 3: 1140-1151.
Pardanani A., Lasho T.L., Finke C. et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86 (12): 1017-1026.
Patnaik M.M., Caramazza D., Gangat N. et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010; 84: 105-108.
Passamonti F., Cervantes F., Vannucchi A.M. et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116: 2857-2858.
Elena C., Passamonti F., Rumi E. et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011; 96: 167-170.
Gangat N., Caramazza D., Vaidya R. et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
Cervantes F. How I treat splenomegaly in myelofibrosis. Blood Cancer J 2011; 1 (10): e37.
Cervantes F., Mesa R., Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377-383.
Martinez-Trillos A., Gaya A., Maffioli M. et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol 2010; 89: 1233-1237.
Thomas D.A., Giles F.J., Albitar M. et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; 106: 1974-1984.
Quintas-Cardama A., Kantarjian H.M., Manshouri T. et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009; 27: 4760-4766.
Kroger N., Holler E., Kobbe G. et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
Ballen K.K., Shrestha S., Sobocinski K.A. et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358-367.
Deeg H.J., Appelbaum F.R. Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. Blood 2011; 117: 7185.
Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
Huang J., Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83: 154-155.
Tefferi A., Verstovsek S., Barosi G. et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009; 27: 4563-4569.
Mishchenko E., Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. Eur J Haematol 2010; 85: 192-199.
Tefferi A., Mesa R.A., Nagorney D.M. et al. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 2000; 95: 2226-2233.
Cervantes F., Mesa R., Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377-383.
Mesa R.A., Nagorney D.S., Schwager S. et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-370.
Barosi G., Ambrosetti A., Centra A. et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630.
Kovaleva L.G., Karagyulyan S.R., Kolosova L.Yu. i dr. Splenektomiya pri subleikemicheskom mieloze. Gematol i transfuziol 2004; 5: 14-21.
Karagyulyan S.R., Grzhimolovskii A.V., Danish'yan K.I. Khirurgicheskie dostupy k selezenke. Annaly khir gepatol 2006; 2: 92-99.
Silaev M.A. Splenektomiya pri massivnoi i gigantskoi splenomegalii u gematologicheskikh bol'nykh: Avtoref. dis. … kand med nauk. M 2012: 15-17.
Galuzyak B.C., Karagyulyan S.R., Ryzhko V.V. i dr. Splenektomiya pri zrelokletochnoi limfome selezenki u bol'nykh starshego vozrasta. Klin gerantol 2004; 5: 20-27.
Galuzyak V.S., Karagyulyan S.R., Ryzhko V.V. i dr. Splenektomiya pri subleikemicheskom mieloze. Gematol i transfuziol 2004; 5: 14-21.
Lyubimova L.S., Savchenko V.G., Mendeleeva L.P. i dr. Transplantatsiya allogennogo kostnogo mozga pri khronicheskom mieloleikoze. Ter arkh 2004; 7: 18-24.
Pokrovskaya O.S., Mendeleeva L.P., Kaplanskaya I.B. i dr. Angiogenez v kostnom mozge bol'nykh mnozhestvennoi mielomoi na razlichnykh etapakh vysokodoznoi khimioterapii. Klin onkogematol 2010; 4: 347-353.